On January 10, 2025, Sichuan Jiuzhang Biotech and Miskawaan Health Group (MHG) held an academic exchange in Bangkok focused on the mechanistic research of botanical medicines in the treatment of tumors, immune-related diseases, antioxidation, and integrative medicine. At the forum, Academician Jiang Jiandong, Chief Scientist of Jiuzhang Biotech, presented the mechanisms by which CHA for Injection exerts its antitumor and immunomodulatory effects. Professor Li Wenbin introduced the results from Phase I and Phase II clinical trials of CHA for Injection. Dr. Johannes Wessolly, representing a team of German physicians, shared his professional insights into the research and application of natural botanical medicines in disease prevention, treatment, anti-aging, and health maintenance. Both parties agreed that natural botanical medicines represent an essential cornerstone in safeguarding human health and wellbeing.

The pharmacological mechanism of CHA for Injection is as follows: CHA targets cellular mitochondria to achieve metabolic and immune reprogramming of tumor cells; it promotes the differentiation of malignant cells into normal-like cells, significantly reducing tumor invasiveness and metastatic potential; it also improves the immunosuppressive microenvironment and enhances antitumor immune responses. These mechanistic findings have been well validated in clinical studies, laying a solid foundation for the further development and application of natural botanical medicines.

Jiang Jiandong, Academician of the Chinese Academy of Engineering,  Chief Scientist of Jiuzhang Biotech 

David Boehm, Founder of MHG 

Academician Jiang Jiandong and David Boehm

Academician Jiang Jiandong had an amiable exchange with the German medical expert team